Phaseline

Targets › LTBR

LTBR (Tumor necrosis factor receptor superfamily member 3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.

Receptor for the heterotrimeric lymphotoxin containing LTA and LTB, and for TNFS14/LIGHT. Activates NF-kappa-B signaling pathway upon stimulation with lymphotoxin (LTA(1)-LTB(2)). Promotes apoptosis via TRAF3 and TRAF5. (UniProt, P36941)

Open in Phaseline: the race on LTBR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mestag TherapeuticsMST-0312
Bispecific antibody targeting lymphotoxin beta receptor (LTBR)
LTBRPhase 1Cancer-NeoplasmsDec 2029

Conditions

Cancer-Neoplasms (1)

Modalities

mixed (1)

Companies

Mestag Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.